1 suspended, 1 unknown. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Suspended 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Immunization, Passive: new trials by email Literature Review of Immunization, Passive trials Research Report on Immunization, Passive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Effectiveness of an Immunobiological Drug in CoViD-19 Anti-SARS-CoV-2, Placebo - COVID-19 Pneumonia, COVID-19 Respiratory Infection | Phase 2 / Phase 3 | Unknown | Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran | 200 | 2021-06-01 | 2021-09-17 |
| GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma autologous immunoglobulin idiotype-KLH conjugate vaccine, cyclophosphamide, doxorubicin hydrochloride - Lymphoma | Phase 3 | Suspended | Favrille | 480 | 2013-12-18 |
COVID-19 (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1)
Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran (1) · Favrille (1)
Argentina (1) · United States (1)